SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IMPROVES QUALITY OF LIFE IN PATIENTS WITH COLD AGGLUTININ DISEASE: PATIENT-REPORTED OUTCOMES RESULTS OF THE PHASE 3 CARDINAL STUDY

• M.M.O. Barros,
• A. Röth,
• W. Barcellini,
• T.H.A. Tvedt,
• Y. Miyakawa,
• D.J. Kuter,
• W. Hobbs,
• J. Su,
• X. Jiang,
• J.M. Arias,
• I.C. Weitz

Affiliations

M.M.O. Barros

Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil

A. Röth

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

W. Barcellini

Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy

T.H.A. Tvedt

Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway

Y. Miyakawa

Thrombosis and Hemostasis Center, Saitama Medical University Hospital, Saitama, Japan

D.J. Kuter

Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, United States

W. Hobbs

Sanofi, Waltham, United States

J. Su

Sanofi, Cambridge, United States

X. Jiang

Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California–Keck School of Medicine, Los Angeles, United States

J.M. Arias

Sanofi, Cambridge, United States

I.C. Weitz

Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California–Keck School of Medicine, Los Angeles, United States